<DOC>
	<DOC>NCT01791049</DOC>
	<brief_summary>TD-1607, administered intravenously as single doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.</brief_summary>
	<brief_title>TD-1607 SAD Study in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<criteria>Subject is a healthy nonsmoking male or a female of nonchild bearing potential and 18 to 50 years old, inclusive, at Screening. Females are considered to be of nonchildbearing potential if they have had a hysterectomy or tubal ligation or are postmenopausal (amenorrheic for at least 2 years) with a folliclestimulating hormone (FSH) level &gt;20 IU/L. Subject has a body mass index (BMI) of 19 to 30 kg/m2, inclusive, and weighs at least 50 kg Subject has evidence or history of clinically significant allergic (except for untreated, asymptomatic seasonal allergies at time of dosing), hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease. Subject has a history of allergies or hypersensitivities to glycopeptide (e.g., vancomycin), penicillin, or cephalosporin antibiotics. Subject has participated in another clinical trial of an investigational drug (or medical device) within 60 days (or 5 halflives, whichever is longer) prior to Screening or is currently participating in another trial of an investigational drug (or medical device).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Gram-positive</keyword>
	<keyword>Infections</keyword>
	<keyword>Bacterial infections</keyword>
</DOC>